Maxim Group analyst Anthony Vendetti maintained a Buy rating on Nuwellis (NUWE – Research Report) yesterday and set a price target of $25.00. The company’s shares opened today at $7.85.
Vendetti covers the Healthcare sector, focusing on stocks such as Nuwellis, Cutera, and Dermata Therapeutics. According to TipRanks, Vendetti has an average return of -0.1% and a 32.26% success rate on recommended stocks.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Nuwellis with a $25.00 average price target, a 218.47% upside from current levels. In a report released today, Lake Street also maintained a Buy rating on the stock with a $25.00 price target.
See today’s best-performing stocks on TipRanks >>
NUWE market cap is currently $4.16M and has a P/E ratio of -0.05.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CHF Solutions, Inc. is a medical device company, which engages in the provision of products for the treatment of fluid overload. Its product include Aquadex FlexFlow System, which provides an ultrafiltration for the removal of salt and water in patients with hypervolemia, or fluid overload. It operates through Cardiac and Coronary Disease Products segment. The company was founded by Crispin Marsh and William S. Peters in November 1999 and is headquartered in Eden Prairie, MN.
Read More on NUWE:
- Nuwellis reports Q4 EPS ($5.00) vs ($41.09) last year
- Nuwellis, Inc. Announces Fourth Quarter and Full Year 2022 Financial Results
- Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
- Nuwellis announces data on role of ultrafiltration in preventing AKI
- Nuwellis, Inc. To Announce Fourth Quarter and Full Year 2022 Financial Results on February 28, 2023
